Summer 2026

Data Science Intern

Advanced Analytics (BioAdvance)

Posted on 5/9/2026

Deadline 5/14/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$22 - $32/hr

Toronto, ON, Canada

In Person

Bachelor's, Master's, MBA

Category
Data & Analytics (1)
Required Skills
LLM
Python
R
SQL
Machine Learning
Data Analysis

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • Currently pursuing a bachelor’s degree in Data Science, Computer Science, Engineering, Statistics, or a related field
  • Experience with Python and/or R and SQL for data analysis
  • Strong analytical, problem-solving, and communication skills
  • Ability to work effectively in a collaborative, fast-paced environment
  • Required Minimum Education: BA/BS
  • 3-5 years of relevant experience through employment or education; ideally with some marketing experience (and/or sales experience)
  • Currently pursuing a MS or MBA with a minimum GPA of 3.0 at an accredited university
  • Undergraduate degree in science, pharmaceuticals, business (marketing)
  • Experience with industry sales/marketing or technology strongly preferred
Responsibilities
  • Collect, clean, and analyze structured datasets to identify trends and insights
  • Support the development and evaluation of machine learning, generative AI, and agentic AI use cases (e.g., autonomous agents, workflow orchestration, decision support)
  • Assist with experimentation and prototyping involving LLMs, GenAI tools, and AI agents
  • Build dashboards, reports, and KPIs using analytics and visualization tools
  • Translate analytical findings into clear, actionable recommendations for business partners
  • Collaborate with cross-functional teams to support analytics and data strategy initiatives
  • Ensure responsible data use, data quality, and compliance with privacy requirements (e.g., PIPEDA)
  • Marketing Execution and Delivery Role will be inclusive of the below: Will be involved in leading the execution of various marketing materials and playbooks designed for our regional counterparts to utilize for upcoming launches
  • Will be involved in cross-functional working on various marketing projects needed for regional deployment
  • Will be part of the marketing team who will utilize market research and customer insights and ensure they are incorporated into all marketing projects
  • Will be a key agency contact for projects he/she leads regarding execution to deliver TAR-200 commercial strategy across all key regions, globally.
  • Drive planning and execution of key TAR-200 activities and processes, such as end to end planning of key external Oncology meetings/engagements, tracking business performance, drive team meetings in alignment with objectives, help monitor execution of planned activities
Desired Qualifications
  • Exposure to Generative AI and large language models (LLMs)
  • Familiarity with agentic AI concepts
  • Experience with data visualization tools such as Power BI or Tableau
  • Understanding of machine learning concepts and model evaluation
  • Prior academic or internship experience working with real-world datasets
  • Strong leadership agility and demonstrated success solving ambiguous business challenges

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 15, 2026 guidance rose to $101.1 billion revenue and $11.68 EPS.
  • OTTAVA launches with select U.S. customers, opening a new robotic surgery category.
  • Tremfya surged 72.5% in Q2 2026, validating J&J's post-Stelara immunology pivot.

What critics are saying

  • Stelara biosimilars cut Q2 2026 sales 55.2%, and drag continues through 2026.
  • July 27, 2026 talc deal still needs 95% claimant approval; future lawsuits remain.
  • Abiomed Impella weakness and electrophysiology pressure threaten MedTech growth into 2027.

What makes Johnson & Johnson unique

  • July 22, 2026 FDA authorization makes OTTAVA the first table-integrated soft tissue robot.
  • J&J's July 15, 2026 quarter topped $25.3 billion, proving multi-engine scale.
  • Tremfya and Darzalex offset Stelara erosion, showing rare pharma portfolio depth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-2%
Yahoo Finance
Aug 15th, 2026
Johnson & Johnson hits record $25.3B quarterly sales, targets $100B annual revenue

Johnson & Johnson shares have surged more than 25% in 2026, outperforming the S&P 500 following strong quarterly results. The healthcare giant reported record quarterly sales of $25.3 billion, marking 6.6% year-over-year growth. The company raised its fiscal year guidance for both sales and adjusted earnings per share. JNJ is now on track to exceed $100 billion in annual revenue for the first time in its history in 2026. As a Dividend Aristocrat, Johnson & Johnson maintains a longstanding commitment to consistent dividend payments and increases, providing shareholders with a reliable income stream alongside capital appreciation.

Yahoo Finance
Aug 10th, 2026
J&J, Equinix, SBAC and one other stock could generate $2,304 annual passive income from $100K investment

Johnson & Johnson leads a portfolio of four dividend-growth stocks that together generate $2,304 in annual passive income from a $100,000 investment split equally. The group delivers a 2.30% blended yield. SBA Communications tops the quartet with a 2.58% yield. Johnson & Johnson brings a 64-year dividend streak and AAA credit rating, making it a core income holding. Equinix, which converted to a REIT in 2015, runs the world's largest neutral interconnection footprint. The company generated $2.63 billion in Q2 revenue and has grown its quarterly payout from $2.66 in 2020 to $5.16 today. Institutions own 99.6% of the float. All four stocks trade on major exchanges with tight spreads, offering liquidity advantages over alternatives like rental real estate or mortgage REITs.

Yahoo Finance
Aug 4th, 2026
JNJ returns $85B to shareholders but stock still lags S&P 500 by 13%

Johnson & Johnson returned $85 billion to shareholders over the past five years through $60 billion in dividends and $25 billion in share buybacks, equivalent to 13.8% of its current market capitalisation. The healthcare giant generated $97.93 billion in revenue over the last twelve months with a 27% operating margin. Despite this substantial cash return, JNJ shareholders saw a total return of 70% over five years, underperforming the S&P 500's 83% return. The company's Innovative Medicine division showed strong performance, with double-digit growth excluding STELARA and successful launches like ICOTYDE. However, the MedTech segment struggled, particularly in cardiovascular, where the Abiomed heart pump business saw sales decline 2%. The performance gap between divisions raises questions about whether returning cash signals disciplined capital allocation or a shortage of high-return growth opportunities.

Yahoo Finance
Jul 31st, 2026
J&J beats estimates with $25.3B revenue, raises guidance to $101.1B for the year

Johnson & Johnson reported strong Q2 2026 results with sales rising nearly 7% to $25.31 billion, beating estimates of $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expected $2.85. The company raised its full-year guidance and remains on track to exceed $100 billion in annual revenue for the first time in its 140-year history. Its pharmaceutical division generated $16.38 billion in quarterly sales. Despite a 55% drop in Stelara revenue to $740 million due to patent loss, newer drugs compensated for the decline. Tremfya sales surged 72.5% to $2 billion, well above the $1.74 billion estimate. Meanwhile, Danaher delivered encouraging Q2 results driven by its Life Sciences business, with bioprocessing orders growing mid-teens despite timing-related revenue fluctuations.

Yahoo Finance
Jul 28th, 2026
J&J to pay $5.5B to settle 76,000 talc baby powder cancer lawsuits

Johnson & Johnson has agreed to pay $5.5 billion to settle approximately 76,000 lawsuits alleging its talc-based baby powder caused ovarian cancer. The settlement requires acceptance by at least 95% of claimants to take effect. The company expects to make an initial payment of no more than $3 billion in 2027, with additional payments due from 2028. Legal representatives suggest the total payout could reach $7 billion or more. The deal is designed to deliver payment to all claimants within 18 months and covers only current claims, leaving future lawsuits outside its scope. J&J maintains the claims lack merit but said the settlement allows it to move forward. The agreement follows three years of halted proceedings whilst J&J pursued unsuccessful bankruptcy strategies through a subsidiary. The company withdrew its talc-based baby powder from US shelves in 2020 and worldwide in 2023.

INACTIVE